Top Page
Inoviq Ltd
(Sydney:IIQ)
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Inoviq Ltd Business Overview & Revenue Model
Inoviq Ltd Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 535.12K | 398.19K | 276.75K | 468.10K | 535.10K | Gross Profit |
| -989.82K | -1.04M | 220.30K | 404.05K | -149.80K | EBIT |
| -7.84M | -10.42M | -8.08M | 280.84K | -2.90M | EBITDA |
| -6.63M | -9.02M | -5.67M | -6.05M | 0.00 | Net Income Common Stockholders |
| -6.55M | -8.97M | -6.51M | -12.37M | -3.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 9.23M | 7.81M | 15.39M | 5.00M | 7.33M | Total Assets |
| 21.71M | 21.51M | 30.78M | 33.52M | 7.37M | Total Debt |
| 403.74K | 730.71K | 998.69K | 1.26M | 0.00 | Net Debt |
| -8.83M | -7.08M | -14.40M | -3.73M | -7.33M | Total Liabilities |
| 1.72M | 1.89M | 2.49M | 4.46M | 899.12K | Stockholders Equity |
| 19.99M | 19.62M | 28.29M | 29.06M | 6.48M |
| Cash Flow | Free Cash Flow | |||
| -4.50M | -7.32M | -6.47M | -6.05M | -2.54M | Operating Cash Flow |
| -4.32M | -7.02M | -6.06M | -5.26M | -2.54M | Investing Cash Flow |
| -174.34K | -292.27K | -411.90K | 2.64M | 0.00 | Financing Cash Flow |
| 5.91M | -267.98K | 16.87M | 286.48K | 2.31M |
Inoviq Ltd Technical Analysis
Inoviq Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
51 Neutral | AU$50.23M | ― | -39.07% | ― | 26.07% | 0.85% | |
| $2.15M | ― | -119.28% | ― | ― | ― | ||
| $77.62M | ― | -99.05% | ― | ― | ― | ||
| $3.71M | ― | -67.69% | ― | ― | ― | ||
51 Neutral | AU$68.68M | ― | -131.55% | ― | 12.53% | -11.04% | |
43 Neutral | AU$83.84M | ― | ― | ― | -33.01% |
Inoviq Ltd Corporate Events
Inoviq Ltd has announced that the suspension of its securities trading will be lifted following the release of further disclosure related to a recent price query. The Australian Securities Exchange (ASX) is continuing its enquiries into Inoviq’s compliance with listing rules, which may impact the company’s market operations and investor confidence.
INOVIQ Limited has announced significant results from its EXO-OC™ ovarian cancer test, presented at the American Society of Clinical Oncology Annual Meeting. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, with no missed early-stage diagnoses. This breakthrough positions INOVIQ as a leader in exosome technology, addressing the critical unmet need for early detection of ovarian cancer. The company plans to further develop and commercialize the test, seeking regulatory approval and aiming to launch it as a Laboratory Developed Test in the US, potentially saving lives by enabling earlier diagnosis and intervention.
Inoviq Ltd’s securities have been suspended from quotation on the ASX following a trading halt initiated on May 26, 2025. The suspension is due to the need for further disclosure regarding issues highlighted in the company’s price query response, and will remain until ASX confirms compliance with its Listing Rules.
INOVIQ Limited responded to an ASX price query by clarifying that the recent abstract published by the American Society of Clinical Oncology (ASCO) does not contain new, price-sensitive information beyond what was previously disclosed. However, the company highlighted the upcoming ASCO Annual Meeting presentation as potentially price-sensitive, emphasizing its confidentiality due to an ongoing patent application process. The company is adhering to ASCO’s strict embargo policies to avoid reputational and commercial risks, and it is ensuring compliance with listing rules while protecting its intellectual property.
INOVIQ Ltd has requested a trading halt on its securities pending an announcement related to an ASX Price Query response. The halt will remain in effect until the company releases the announcement or until normal trading resumes on 28 May 2025. This move is part of the company’s compliance with ASX listing rules and aims to ensure transparency and proper dissemination of information to stakeholders.
Inoviq Ltd has announced the cessation of 166,667 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could influence investor perception regarding the company’s ability to meet certain conditions tied to its securities.
INOVIQ Limited has made significant advancements in its exosome programs, including expanding its customer base for the EXO-NET technology across Europe, the US, and Asia, and developing AI-enhanced algorithms for early ovarian cancer detection. The company has also engaged the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for triple-negative breast cancer and published diagnostic performance results for its neuCA15-3 test. Additionally, INOVIQ has established a Medical and Scientific Advisory Board and appointed Dr. Emma Ball as Chief Commercial Officer. These developments are expected to enhance INOVIQ’s industry positioning and offer new therapeutic options for cancer patients.
Inoviq Ltd has announced the issuance of 150,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.
Inoviq Ltd has announced the application for quotation of 106,100 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code IIQ. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, impacting its stakeholders positively.
Inoviq Ltd has announced a proposed issue of 106,100 ordinary fully paid securities, with the issuance date set for April 7, 2025. This move is part of a placement or other type of issue, and the company has applied for the quotation of these securities on the Australian Securities Exchange (ASX). This strategic financial maneuver is likely aimed at raising capital to support Inoviq’s ongoing projects and strengthen its market position in the biotechnology sector.
INOVIQ Limited has released an investor briefing detailing its CAR-exosome therapeutic program. The announcement highlights the company’s ongoing efforts to advance its therapeutic solutions, which could potentially enhance its market position in the biotechnology sector. The briefing underscores the speculative nature of investments in the company, emphasizing that future performance and returns are not guaranteed.
INOVIQ Ltd announced the publication of a scientific paper in the journal Breast Cancer Research and Treatment, highlighting the superior diagnostic performance of its neuCA15-3 test compared to the FDA-approved CA15-3 test for breast cancer monitoring. The neuCA15-3 test demonstrated an overall accuracy of 81% and showed potential for early-stage breast cancer detection when combined with other biomarkers. This milestone supports the test’s commercialization and partnering opportunities, with plans to further develop it for early detection and implement it on existing pathology instruments.
INOVIQ Ltd has partnered with the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for treating solid tumors, specifically targeting Triple Negative Breast Cancer (TNBC). The collaboration involves in vitro and in vivo studies under a Master Service Agreement, with the aim of achieving significant milestones in the development of CAR-exosome therapy, potentially leading to Phase I clinical studies. This partnership is expected to enhance INOVIQ’s position in the cancer therapeutics industry by leveraging Peter Mac’s expertise in immunotherapy, thereby accelerating the development and potential market introduction of this innovative therapy.
Inoviq Ltd has announced that Biotech Capital Management Pty Ltd, acting as an investment manager for the Merchant Biotech Fund, has ceased to be a substantial holder in the company. This change occurred after the sale of 2,050,000 shares, reducing the voting power of the Merchant Biotech Fund to 4.64%. This development may impact Inoviq Ltd’s shareholder structure and could influence future investment strategies or stakeholder decisions.
INOVIQ Limited announced that its CEO, Dr. Leearne Hinch, will present at the ShareCafe Small Cap ‘Sip and Learn’ Webinar on March 19, 2025. This presentation is part of INOVIQ’s efforts to engage with investors and stakeholders, potentially impacting the company’s visibility and positioning within the biotechnology industry.
INOVIQ Ltd has appointed Dr. Emma Ball as Chief Commercial Officer, effective April 22, 2025. Dr. Ball brings extensive experience from CSL Ltd and Illumina Inc, and will lead commercial efforts to advance INOVIQ’s technologies and products. Her expertise is expected to significantly impact the company’s strategic partnerships and commercialization efforts, particularly in advancing ovarian cancer screening tests and CAR-exosome therapy for breast cancer.
Inoviq Ltd has announced a change in the interests of its director, Philip Powell, who has acquired an additional 50,000 ordinary fully paid shares at $0.35 per share. This purchase increases Powell’s total holdings to 584,630 ordinary shares, along with other options, reflecting a potential vote of confidence in the company’s prospects.
Inoviq Ltd has announced a change in the director’s interest, specifically involving Max Johnston, who has increased his indirect holding in the company by acquiring 200,000 ordinary fully paid shares. This acquisition, conducted through Jondol Pty Ltd, reflects a significant investment in the company’s stock, potentially indicating confidence in Inoviq’s future prospects and stability. The transaction was executed on the market at a price of $0.35 per share, and it may have implications for stakeholders by potentially influencing market perceptions of the company’s value and director confidence.